Results 11 to 20 of about 44,651 (208)

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C [PDF]

New England Journal of Medicine, 1998
BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy. We compared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of interferon alfa-2b
Albrecht, Janice K., , Ph.D., Cort, Susannah, , M.D., Goodman, Zachary D., , M.D., Ph.D., Gordon, Stuart C., , M.D., Lee, William M., , M.D., Ling, Mei-Hsui, , Ph.D., McHutchison, John G., , M.D., Rustgi, Vinod K., , M.D., Schiff, Eugene R., , M.D., Shiffman, Mitchell L., , M.D.   +9 more
core   +4 more sources

A Phase 3 clinical trial validating the potency and safety of an innovative, extra‐long‐acting interferon in chronic hepatitis C

JGH Open, 2022
Background and Aim Ropeginterferon alfa‐2b is a novel mono‐pegylated, extra‐long‐acting interferon. It is administered infrequently and showed good tolerability and clinical activity for the chronic hepatitis B or C treatment in our previous Phase 2 ...
Chi‐Yi Chen, Wan‐Long Chuang, Albert Qin, Wen‐Hua Zhang, Li‐Ying Zhu, Guo‐Qiang Zhang, Jyh‐Jou Chen, Ching‐Chu Lo, Xinmin Zhou, Xiaorong Mao, Jia Shang, Hsing‐Tao Kuo, Wen Xie, Chien‐Hung Chen, Gin‐Ho Lo, Dae W Jun, Shuangsuo Dang, Chan‐Yen Tsai, Ting‐Fang Wang, Hsin‐Hui Lai, Kuan‐Chiao Tseng, Yi‐Wen Huang, Pei‐Jer Chen   +22 more
doaj   +1 more source

Modern opportunities of interferons in treatment of children with COVID-19

Медицинский совет, 2021
Introduction. In 2020, most doctors were at the frontlines in the fight against the novel coronavirus infection (COVID-19). In the process of searching for effective etiotropic drugs, news came in that type I interferons had been successfully used for ...
Asiya I. Safina, Olga V. Sharipova, Ildus Ya. Lutfullin, Olga S. Naumova, Maria A. Daminova   +4 more
doaj   +1 more source

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis : Fundamentals Of Care for UveitiS (FOCUS) Initiative [PDF]

, 2018
Supplemental material available at www.aaojournal.org. Supported by AbbVie, Inc., and the Fundamentals of Care for Uveitis Initiative National Faculty.
Accorinti, Massimo, Acharya, Nisha, Adan, Alfredo, Agrawal, Rupesh, Akkoc, Nurullah, Al Ghamdi, Saed, Al Ghamdi, Turki, Al Saati, Anood, Al-Dhibi, Hassan A., Al-Shamarani, Mohamed, Alsabaani, Nasser, Bachta, Artur, Barisani-Asenbauer, Talin, Beare, Nicholas, Belfort, Rubens, Blanco, Ricardo, Brézin, Antoine P., Carreño, Ester, Chandran, Vinod, Chee, Soon Phaik, Chiquet, Christophe, Chng, Hiok Hee, Cimbalas, Andrius, Cimino, Luca, Cordero-Coma, Miguel, Cristobal, Couto, Cuevas, Miguel, Davis, Janet L., de Boer, Joke, de la Torre, Alejandra, De Schryver, Ilse, Derzko-Dzulynsky, Larissa, Diaz-Valle, David, Dick, Andrew D., Eurico da Fonseca, João, Facsko, Andrea, Figueira, Luis, Fundamentals of Care for Uveitis International Consensus Group, Kuffova, Lucia, Merino, Claudia Eugenia Duran, Murphy, Conor, Nascimento, Heloisa, Porto, Fernanda Belga Ottoni, Ramanan, Athimalaipet V., Rosenbaum, James T., Salah, Sawsen, Salek, Sherveen, Siak, Jay, Sonoda, Koh Hei, Steeples, Laura, Yee, Anita Chan Sook   +50 more
core   +4 more sources

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial

Annals of Hepatology, 2003
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection.
Francisco Bosques-Padilla, MD, Rafael Trejo-Estrada, MD, Octaivio Campollo-Rivas, MD, Carlos Cortez-HernÁndez, MD, Margarita Dehesa-Violante, MD, Héctor Maldonado-Garza, MD, Raúl Pérez-Gómez, MD, Armando Cabrera-Valdespino, MD   +7 more
doaj   +1 more source

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [PDF]

, 2002
BACKGROUND Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety
Carosi, Giampiero, , M.D., Craxi, Antonio, , M.D., Dhumeaux, Daniel, , M.D., Diago, Moises, , M.D., Fried, Michael W., , M.D., Gonçales, Fernando L., , Jr., M.D., Hoffman, Joseph, , M.D., Häussinger, Dieter, , M.D., Lin, Amy, , M.S., Marinos, George, , M.D., Reddy, K. Rajender, , M.D., Shiffman, Mitchell L., , M.D., Smith, Coleman, , M.D., Yu, Jian, , M.D., Ph.D.   +13 more
core   +2 more sources

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables [PDF]

, 1993
Pretreatment variables that could predict the response of chronic hepatitis C to interferon alfa treatment have not been fully assessed. Eighteen baseline variables were evaluated in a series of 100 consecutive patients treated with a 12 month course of ...
Camps, J. (J.), Civeira, M.P. (María Pilar), Cosin, O. (Octavio), Garcia-Granero, M. (Marta), Prieto, J. (Jesús), Riezu-Boj, J.I. (José Ignacio)   +5 more
core   +1 more source

SIDE EFFECTS OF VARIOUS SCHEMES OF INTERFERON THERAPY OF CHRONIC HEPATITIS C AND THEIR CORRECTION

Медицинский совет, 2017
The aim of this work was to assess the frequency and severity of major interferon-induced side effects depending on the applied interferon drug. The study included 29 patients with chronic hepatitis C with genotype 1b, 2, 3a/b.
A. M. Ryumin, O. L. Sobolevskaya, O. V. Korochkina   +2 more
doaj   +1 more source

Kaposi's sarcoma in a patient with erythroblastopenia and thymoma: Reactivation after topical corticosteroids [PDF]

, 1998
We report a 69-year-old female with erythroblastopenia and thymoma who developed lesions of Kaposi's sarcoma (KS) after thymectomy, 2 months after the initiation of therapy with methylprednisolone.
Alomar, A., Barnadas, M. A., Curell, R., de Moragas, J. M., Garcia-Patos, V., Kind, P., Pedro, C., Perez, E., Sander, C. A.   +8 more
core   +1 more source

An expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]

, 2018
BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.
Abbas, Abbas, Ahn, Beasley, Beasley, Bisceglie, Bogr, Brown, Buti, Centers for Disease Control, Chae, Chan, Chang, Chang, Chang, Chang, Chang, Chao, Chaung, Chen, Chen, Chen, Chen, Chi, Chien, Choe, Chu, Clemente, Della Corte, European Association for the Study of the Liver, Evans, Fang, Fattovich, Fontana, Fung, Gish, Hadziyannis, Halperin, Hann, Heathcote, Hongthanakorn, Hoofnagle, Hu, Huang, Hung, Hyun, Iino, Iloeje, Jeng, Keeffe, Kim, Komatsu, Konstantinou, Kowdley, Kuo, Kwong, Lai, Lai, Lai, Lai, Lampertico, Lau, Lau, Lee, Lee, Liang, Liaw, Liaw, Liaw, Liew, Lin, Lin, Lin, Liu, Liu, Liu, Lok, Lok, Lok, Loomba, MacLachlan, Manegold, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Martin, Martin-Carbonero, Mast, McClune, McMahon, Mitchell, Monte, Murata, Mutimer, Nafa, Nguyen, Nguyen, Nikolopoulos, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Papatheodoridis, Park, Park, Park, Patterson, Perrillo, Perrillo, Pollack, Prati, Qiu, Reijnders, Sarin, Seto, Seto, Sherman, Shim, Shiraki, Sinatra, Sinn, Soriano, Stevens, Takano, Takayama, Takkenberg, Terrault, Thibault, Thio, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tse, Wang, Wedemeyer, Wei, Wen, Wiseman, Wursthorn, Xie, Xu, Yi, Yi, Yu, Yu, Yuen, Yuen, Yuen, Yuen, Yuen, Zhang, Zhang, Zhang, Zou   +173 more
core   +2 more sources